ArticleClinical and translational radiation oncology2025
Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score matched analysis.
Article in Clinical and translational radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Postoperative radiotherapy or chemoradiotherapy versus surgery only in non-metastatic head and neck adenoid cystic carcinoma: a retrospective analysis.Translational cancer research · 2026Article
- Advanced radiotherapy and systemic therapy in head and neck adenoid cystic carcinoma: Current progress and future integrated strategies.Translational oncology · 2026Review
- Letter to the Editor: Reply to Topkan et al.Clinical and translational radiation oncology · 2025Article
- Comment on: Concurrent chemoradiotherapy versus radiotherapy alone in postoperative high-risk adenoid cystic carcinoma of the head and neck: A propensity score-matched analysis.Clinical and translational radiation oncology · 2025Article
- Proton therapy achieves high-dose tumor control with organ preservation in complex metastatic adenoid cystic carcinoma: a case report of a refractory patient with 16 pulmonary metastases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of concurrent chemoradiotherapy (CCRT) in postoperative head and neck adenoid cystic carcinoma (ACC) remains controversial due to the limited evidence from randomized trials. This study assessed the effectiveness of CCRT by comparing a prospective CCRT group with a retrospective radiation（RT） alone group using propensity score matching (PSM). Methods and materials: Postoperative head and neck ACC patients with T3-4/N1-3 M0 disease or after R1/R2 resection were enrolled. All patients underwent intensity-modulated radiation therapy (IMRT), and CCRT group received two cycles of concurrent docetaxel and nedaplatin. To ensure comparability, PSM were utilized. Following PSM, survival outcomes were analyzed using Kaplan-Meier curves and compared using the log-rank test. Results: A prospective CCRT group of 55 patients and a retrospective RT alone group of 160 patients were included. The multivariate Cox regression analysis showed no association between CCRT and overall survival (OS) (hazard ratio [HR] = 0.71, 95 %CI: 0.24-2.08, p = 0.537), or other survival outcomes. To mitigate potential confounding factors, a 1: 1 PSM analysis was performed. With a median follow-up of 51 months, post-PSM analysis (including 48 patients in each group) indicated no significant differences in OS (estimated 5-year OS rates: 90.7 % versus 84.3 %, p = 0.331), locoregional recurrence-free survival (LRRFS) (p = 0.261), distant metastasis-free survival (DMFS) (p = 0.425), or disease-free survival (DFS) (p = 0.600) between two groups. The multivariate Cox regression analysis also showed no association between CCRT and OS (HR = 0.29, 95 %CI: 0.06-1.38, p = 0.119), or other survival outcomes. Conclusion: The addition of concurrent chemotherapy to postoperative IMRT did not confer a survival benefit in terms of LRRFS, DMFS, DFS, or OS in patients with head and neck ACC. Upcoming results from randomized studies are anticipated to shed more light on this debated issue. CCRT should be avoided outside of clinical trials.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.